GlassScriptPhysician profile
Christopher Grant Staples
NPI 1568783595
$4,558.89
in general payments reported to CMS, 2019-2025
22 companies · $1,567 in 2025
The $1,567 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $395 · 2022: $501 · 2023: $810 · 2024: $1,286 · 2025: $1,567.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,275 · Education: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,275.03 |
| Education | $387.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,145.12 | 2021-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $592.09 | 2021-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $404.79 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $364.68 | 2024-2025 | Tremfya, Simponi Aria, Simponi |
| E.R. Squibb & Sons, L.L.C. | $362.99 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $230.12 | 2021-2025 | |
| Ucb, INC. | $206.69 | 2024-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $174.33 | 2021-2025 | Adbry |
| Amgen INC. | $169.69 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $167.02 | 2022-2025 | |
| Lilly USA, LLC | $156.42 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Pfizer INC. | $141.29 | 2022-2025 | |
| Organon LLC | $124.99 | 2025 | Hadlima, Vtama |
| Incyte Corporation | $104.57 | 2022-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $46.72 | 2024-2025 | Cabtreo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $37.51 | 2021 | |
| Organogenesis INC. | $34.81 | 2022 | |
| Mimedx Group, INC. | $26.47 | 2025 | |
| Journey Medical Corporation | $24.06 | 2025 | |
| Dermavant Sciences, INC. | $15.06 | 2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.87 | 2024 | Spevigo |
| Almirall LLC | $14.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Staples listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.